$7.46
0.27% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US1710774076
Symbol
CDXC

ChromaDex Corporation Stock price

$7.46
+3.99 114.99% 1M
+4.34 139.10% 6M
+6.03 421.68% YTD
+6.02 418.06% 1Y
+2.46 49.20% 3Y
+3.76 101.62% 5Y
+6.30 544.21% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.02 0.27%
ISIN
US1710774076
Symbol
CDXC
Industry

Key metrics

Market capitalization $569.82m
Enterprise Value $540.32m
P/E (TTM) P/E ratio 394.71
EV/FCF (TTM) EV/FCF 136.10
EV/Sales (TTM) EV/Sales 5.89
P/S ratio (TTM) P/S ratio 6.22
P/B ratio (TTM) P/B ratio 16.50
Revenue growth (TTM) Revenue growth 9.95%
Revenue (TTM) Revenue $91.67m
EBIT (operating result TTM) EBIT $3.65m
Free Cash Flow (TTM) Free Cash Flow $3.97m
Cash position $32.40m
EPS (TTM) EPS $0.02
P/E forward 248.67
P/S forward 5.86
EV/Sales forward 5.56
Short interest 5.26%
Show more

Is ChromaDex Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

ChromaDex Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a ChromaDex Corporation forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a ChromaDex Corporation forecast:

Buy
100%

Financial data from ChromaDex Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
92 92
10% 10%
100%
- Direct Costs 35 35
5% 5%
39%
56 56
13% 13%
61%
- Selling and Administrative Expenses 45 45
5% 5%
49%
- Research and Development Expense 5.86 5.86
15% 15%
6%
5.15 5.15
285% 285%
6%
- Depreciation and Amortization 1.50 1.50
16% 16%
2%
EBIT (Operating Income) EBIT 3.65 3.65
180% 180%
4%
Net Profit 1.49 1.49
123% 123%
2%

In millions USD.

Don't miss a Thing! We will send you all news about ChromaDex Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ChromaDex Corporation Stock News

Neutral
Business Wire
12 days ago
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, announces that its flagship patented nicotinamide riboside (NR) ingredient, Niagen®, is the hero ingredient in Longevity.Technology's inaugural supplement called Longevity.Technology® LONGEVITY. Designed...
Neutral
Business Wire
19 days ago
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced the nationwide rollout of its pharmaceutical-grade nicotinamide riboside chloride (NRC) products, Niagen® IV, now accessible at over 200 Restore Hyper Wellness locations across the United States...
Neutral
Seeking Alpha
25 days ago
ChromaDex Corporation (NASDAQ:CDXC ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Ben Shamsian - IR Rob Fried - CEO Ozan Pamir - CFO Andrew Shao - SVP, Scientific & Regulatory Affairs Wesley Yu - VP, Finance Conference Call Participants Jeff Cohen - Ladenburg Thalmann & Co. Edward Marks - H.C. Wainwright Bill Dezellem - Tieton Capital Management Sean McGowan...
More ChromaDex Corporation News

Company Profile

Chromadex Corp. is a nutraceutical company. The firm engages in acquiring, developing and commercializing proprietary-based ingredient technologies. It operates through the following segments: Ingredients, Consumer Products, and Analytical Reference Standards and Services. The Ingredients segment offers NIAGEN in an ingredient form to partners. The Consumer Products segment sells TRU NIAGEN to improve health by safely raising NAD levels. The Analytical Reference Standards and Services segment provides product regulatory approval and scientific advisory services to the clients in the food, supplement, and pharmaceutical industries. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in September 1999 and is headquartered in Los Angeles, CA.

Head office United States
CEO Robert Fried
Employees 106
Founded 1999
Website www.chromadex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today